Point72 Asset Management’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Point72 Asset Management’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-26,512	Closed	-$71.1K	–	2908
2023 Q1	$71.1K	Sell	26,512 -41,088	-61%	-$197K	﹤0.01%	1703
2022 Q4	$367K	Buy	+67,600	New	+$567K	﹤0.01%	1183
2021 Q3	–	Sell	-399,844	Closed	-$8.77M	–	1278
2021 Q2	$8.77M	Buy	399,844 +249,908	+167%	+$5.55M	0.04%	488
2021 Q1	$3.61M	Buy	149,936 +142,736	+1,982%	+$3.32M	0.02%	635
2020 Q4	$130K	Buy	+7,200	New	+$108K	﹤0.01%	871
2020 Q3	–	Sell	-104,157	Closed	-$2.53M	–	1133
2020 Q2	$2.53M	Buy	+104,157	New	+$1.72M	0.02%	562
2018 Q3	–	Sell	-120,865	Closed	-$5.25M	–	1264
2018 Q2	$5.25M	Sell	120,865 -103,135	-46%	-$4.42M	0.02%	592
2018 Q1	$8.3M	Buy	224,000 +24,000	+12%	+$640K	0.03%	463
2017 Q4	$3.97M	Buy	+200,000	New	+$4.3M	0.02%	635

Other funds holding GTHX

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 Asset Management's GTHX Position: Q2 2023 in Review

Point72 Asset Management sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q2 2023, closing a stake of 26,512 shares — an estimated $71.1K sold.

Point72 Asset Management first reported a position in GTHX in Q4 2017 and held it in 9 quarters. The position peaked at $8.77M in Q2 2021. 80 funds tracked by Wall St. Rank hold GTHX as of Q2 2023.

Point72 Asset Management reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Point72 Asset Management sold 26,512 G1 Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $71.1K.
Point72 Asset Management first reported a position in G1 Therapeutics, Inc. Common Stock in Q4 2017 and held it in 9 quarters.
Point72 Asset Management's G1 Therapeutics, Inc. Common Stock position peaked at $8.77M in Q2 2021.
80 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Point72 Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.